Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 16,097	$ 33,509
Short-term bank deposits	9,003
Accounts and note receivables, net	18,622	15,552
Inventories, net	5,635	4,281
Prepaid assets	1,153	1,547
Other current assets	1,722	1,045
Total current assets	53,519	57,221
Property and equipment, net	23,672	23,288
Intangible assets, net	186	205
Right-of-use assets	2,097	489
Land use rights, net	1,464	1,493
Deferred tax assets	5,075	4,695
Long-term certificates of deposit	28,799	23,431
Other assets, noncurrent	1,278	995
Total assets	120,929	116,539
Current liabilities:
Accounts payable	271	355
Deferred revenue	57	39
Due to related parties	1,484	1,369
CVR excess closing cash payable	328	1,085
Accrued expenses and other current liabilities	10,513	11,935
Income tax payable	2,262	5,054
Operating lease liabilities, current	659	210
Total current liabilities	15,574	20,047
Operating lease liabilities, noncurrent	1,297	199
Deferred government grants	192	213
CVR derivative liability, noncurrent	4,839	4,722
Warrant liability, noncurrent	5,634	12,835
Other noncurrent liabilities	47	49
Total liabilities	27,583	38,065
Commitments and Contingencies (Note 12)
Stockholders' equity:
Common stock, $0.001 par value, 400,000,000 shares authorized; 85,537,774 shares and 76,595,616 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	85	77
Additional paid-in capital	133,656	68,179
Statutory reserve	3,098	3,098
Accumulated deficit	(74,478)	(85,538)
Accumulated other comprehensive loss	(2,010)	(1,644)
Total Gyre stockholders' equity (deficit)	60,351	(15,828)
Noncontrolling interest	32,995	29,777
Total equity	93,346	13,949
Total liabilities, convertible preferred stock, and equity	120,929	116,539
GC Biopharma Corp
Current assets:
Long-term receivable from GCBP	4,839	4,722
GNI
Current assets:
Other receivables from GNI	$ 1,287	1,287
Convertible Preferred Stock
Current liabilities:
Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively		$ 64,525